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Background: Rheumatoid arthritis is characterised by inflammation and an increased cardiovascular risk. It
was recently shown that active early rheumatoid arthritis is associated with dyslipidaemia, which may
partially explain the enhanced cardiovascular risk. However, it is unknown when this dyslipidaemia starts.
Objective: To investigate the progression of the lipid profile over time and the influence of inflammatory
parameters on this lipid profile, in people who later developed rheumatoid arthritis.
Methods: Levels of total cholesterol, high-density lipoprotein cholesterol (HDLc), triglycerides, apolipoprotein
AI (apo AI), apolipoprotein B (apo B) and lipoprotein(a) (Lp(a)) were determined in 1078 stored, deep-
frozen, serial blood bank samples, collected between 1984 and 1999, of 79 blood donors who later
developed rheumatoid arthritis. These samples were compared with 1071 control samples of unselected
blood donors, matched for age, sex and storage time.
Results: Samples of patients who later developed rheumatoid arthritis showed, on average, 4% higher total
cholesterol, 9% lower HDLc, 17% higher triglyceride and 6% higher apo B levels than matched controls
(p(0.05).
The magnitude of the differences in lipid levels between groups, explained by C reactive protein (CRP), was
limited. For example, only 3.6% of the difference in HDLc levels between the groups was explained by the CRP
concentrations.
Conclusion: Patients who later develop rheumatoid arthritis have a considerably more atherogenic lipid
profile than matched blood donors at least 10 years before onset of symptoms. As inflammation only
marginally explains the differences between the two groups, a modulating effect of lipids on inflammatory
processes is hypothesised.
R
heumatoid arthritis, an inflammatory joint disease, is
associated with increased cardiovascular morbidity and
mortality, as shown by several inception cohort studies.1–6
The cause of this enhanced cardiovascular risk is unknown, but
inflammation is thought to play an important part,7 which is in
line with the accumulating evidence that inflammation has a
prominent role in the development of atherosclerosis.8 9 The
relevance of inflammation in the development of cardiovascular
disease is shown by associations between future cardiovascular
events and raised C reactive protein (CRP) levels.10–13 The
underlying pathophysiological mechanism has not yet been
completely elucidated and several possibilities have been
suggested. Acute-phase proteins might: (1) deteriorate ‘‘fatty
streaks’’ into (instable) plaques,9 (2) destabilise plaques and
cause plaque ruptures,12 (3) give complement activation13 or (4)
facilitate deterioration of the lipid profile.14
Dyslipidaemia may be responsible for the increased cardio-
vascular risk in patients with rheumatoid arthritis. Several
investigators have shown that active rheumatoid arthritis is
associated with an unfavourable lipid profile—that is, a
decreased total cholesterol and relatively lower high-density
lipoprotein cholesterol (HDLc) levels.14–16 The result is a less
favourable atherogenic index, suggesting a relationship
between inflammation and dyslipidaemia.
Other lipoproteins have been suggested to play an important
part in the development of atherosclerosis—that is, lipopro-
tein(a) (Lp(a)), apolipoprotein AI (apo AI) and apolipoprotein
B (apo B). A few studies have investigated Lp(a) levels in
patients with rheumatoid arthritis, and the results are contra-
dictory. Several earlier studies showed considerably lower Lp(a)
levels in patients with rheumatoid arthritis and a marked
association with acute-phase response.17 A later study found
neither considerably raised levels of Lp(a) in patients with
rheumatoid arthritis nor a notable relationship between Lp(a)
and the acute-phase response.18 Evidence is growing that both
apo AI and apo B are useful predictors for future cardiovascular
risk. Apo AI may protect against cardiovascular disease,
whereas apo B may increase cardiovascular risk.19–21 Apo AI is
the major apolipoprotein in HDLc and has various structural
and functional roles in HDLc metabolism. Apo B is the main
apolipoprotein of chylomicrons, very low-density, low-density
and intermediate-density lipoproteins, and seems to be a better
predictor for cardiovascular disease than low-density lipopro-
tein cholesterol.22 So far, data regarding apolipoproteins in
rheumatoid arthritis are sparse and contradictory.
Recently, we showed that in a large group of blood donors,
the presence of a preclinical phase preceding the actual
clinical phase of rheumatoid arthritis is characterised by
serological changes—that is, raised levels of immunoglobulin
Abbreviations: anti-CCP, anti-cyclic citrullinated peptides; apo AI,
apolipoprotein AI; apo B, apolipoprotein B; CRP, C reactive protein; HDLc,
high-density lipoprotein cholesterol; IgM-RF, immunoglobulin M
rheumatoid factor; Lp(a), lipoprotein(a); sPL-A2, secretory phospholipase
A2
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M rheumatoid factor (IgM-RF) and anti-cyclic citrullinated
peptides (anti-CCP).23 In addition, we also found raised CRP
levels in the samples of the blood donors who later developed
rheumatoid arthritis compared with samples with random
control donors.24 Furthermore, the presence of dyslipidaemia in
early active rheumatoid arthritis raises the question of whether
or not this phenomenon starts in the preclinical phase of
rheumatoid arthritis.
This study was undertaken to investigate the lipid profile
over time and its relationship with inflammation and serolo-
gical markers, in patients who later developed rheumatoid
arthritis.
METHODS
Participants
The Sanquin Blood Bank Northwest Region, formerly the Red
Cross Blood Bank, in Amsterdam, The Netherlands, serves an
area with about 2 million inhabitants. The blood bank stores
1 ml aliquots of serum at 230 C˚, from each donation since
1984. On average, donors donate blood 2–4 times a year over a
long-term period. The maximum age of donors is 70 years.
Within the area in which the blood bank collects blood from
donors, most of the patients with rheumatoid arthritis are
registered in the Jan van Breemen Institute, a regional network
of rheumatology outpatient clinics. After receiving approval
from the local institutional review board, all registered patients
with rheumatoid arthritis were sent a letter asking them if they
had been a blood donor before the symptoms of rheumatoid
arthritis started. When the reply was positive, patients were
asked to sign informed consent, permitting the use of stored
blood samples for the present study. Ultimately, we identified
79 non-related patients with rheumatoid arthritis, satisfying
the 1987 American College of Rheumatology criteria for
rheumatoid arthritis.25 Chart review yielded the following data:
time of the start of symptoms, time of diagnosis of rheumatoid
arthritis, IgM-RF at the time of diagnosis and during follow-up,
and the presence of bony erosions on radiographs.
Procedures
From 1984 to 1999, patient samples were collected long-
itudinally from each consecutive blood donation. This was done
during the entire period in which the patients were blood
donors. For each sample of every patient with rheumatoid
arthritis, one control sample from a random blood donor
matched for sex, age (SD 3 years) and time of blood donation
was selected as described earlier.23 24 This method of control
selection was chosen to ensure identical storage conditions for
the materials from patients and controls.
Laboratory measurements
Serum total cholesterol (,5.0 mmol/l) and triglycerides
(,2.2 mmol/l) were analysed by an enzymatic method using
the appropriate assays supplied by Roche Diagnostics (Almere,
The Netherlands), on a Hitachi 911 analyzer (Roche
Diagnostics), according to the instructions of the manufacturer.
Polyethylene glycol modified enzymes were used to assess
HDLc levels (in men, .0.9 mmol/l; in women, .1.1 mmol/l).
Apo AI (in men, 1.04–2.02 g/l; in women, 1.08–2.25 g/;), apo B
(in men, 0.66–1.33 g/l; in women, 0.60–1.17 g/l) and Lp(a)
(,30 mg/dl) were analysed by an immunoturbidimetric
method, using appropriate assays (Roche Diagnostics). CRP
(,10 mg/l) was measured using a latex-enhanced highly
sensitive assay (Roche Diagnostics). Secretory phospholipase
A2 (sPLA2; ,5 ng/ml) was measured by means of a highly
sensitive ELISA (Sanquin Research at CLB, Amsterdam, The
Netherlands).
IgM-RF and anti-CCP antibodies were measured using in-
house ELISAs on an ES 300 analyzer (Roche Diagnostics).23 24
IgM-RF was calibrated with a national reference serum
containing 200 IU/ml. No reference serum is available for
anti-CCP. The applied criteria for positive tests were >30 IU/ml
for IgM-RF and >50 AU/ml for anti-CCP.
Statistics
We divided the data into 1-year periods before the start of the
symptoms and we used the samples from 10 to 0 years before
the start of the symptoms to estimate the time course of the
different lipids. Samples from 15–10 years before the start of
the symptoms were omitted because of the small number of
available samples. The time course was estimated using a
random coefficient multilevel regression analysis—that is, a
longitudinal regression technique that allows both starting
levels and progression over time to differ between subjects.26
Multilevel regression analysis can be seen as a longitudinal
linear regression analysis, which combines many cross-sec-
tional linear regression models into one model of one variable
over time. In our study, we looked at the lipid levels over time
and investigated the influence of being a future patient or a
control and the influence of inflammation parameters on the
progression of the various lipid levels over time. Multilevel
regression analysis quantifies these influences, or rather
associations, between the lipid levels and these two sets of
variables, and tests within for significance.
In addition to this increase of statistical power by combining
the cross-sectional data of various time points into one
association, the multilevel method enables the user to correct
for confounding caused by multiple testing within subjects.
The differences in triglyceride and Lp(a) levels between
patients and controls were reported as the differences in
geometric means, as these variables were non-normally
distributed. Subsequently, the natural logarithm of these levels
was used for the analyses.
Preceding the time course analysis, it was investigated
whether the various lipid levels were constant over time or if
there were increases or decreases in certain 1-year periods.
The first step of modelling the data was carried out to
determine differences between patients and controls in the lipid
levels over time. These differences were reported as absolute
values and as percentages of the mean lipid levels as measured
in the control groups. The possibility of interaction between
time and group was also investigated in this model. In the
second step of this analysis, CRP, IgM-RF and anti-CCP were
added to the model to investigate whether the difference
between patients and controls could be explained by CRP, IgM-
RF or anti-CCP. The differences in the various lipid concentra-
tions between patients and controls, which could be explained
by CRP, IgM-RF or anti-CCP, were reported as percentages of
the observed total differences between the two groups. We also
added another acute-phase reactant to the model—that is,
sPLA2—to investigate whether this would have additional
value.
In another analysis, the longitudinal relationships between
the lipids and CRP, IgM-RF and anti-CCP were analysed for
patients and controls combined into one group. Firstly, a model
investigating variables measured at the same time was used.
Secondly, a ‘‘time-lag’’ –model, in which the relationship
between the lipid concentrations of a particular 1-year period
with inflammation or serological markers of a previous 1-year
period, was investigated.26
The random coefficient analyses were carried out using the
statistical program MLwiN.27 A p value ,0.05 was considered
significant.
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RESULTS
Patient characteristics
We included 79 patients with rheumatoid arthritis, 61% were
women, with a mean age of 51 years at the onset of symptoms.
The range of available serum samples was 1–51, with a median
of 13 samples per patient. The first sample was taken at a
median of 7.5 (range 0.1–14.5) years before the onset of
symptoms. For serum samples from seven patients, no matched
control sera were available, resulting in a total of 1078 serum
samples of patients and 1071 from controls.
Lipid levels
Figure 1 shows the development of lipid levels over time as
measured in blood samples of the patients and controls. An
investigation of the total cholesterol, HDLc, triglyceride, apo AI,
apo B and Lp(a) levels, using the 1-year periods separately,
yielded no trend breach in the progression of lipid levels over
time; in other words, the increase or decrease in lipid levels was
constant over time. This justified time course estimations in
which the 1-year periods were investigated as one whole period.
The first step modelling the data yielded significant
differences in lipid levels between patients and controls.
Mean total cholesterol levels were higher in the patients than
in the controls, on average 0.21 mmol/l (p = 0.05). Triglyceride
and Apo B levels were also higher in patients than in controls,
on average 0.26 mmol/l (p,0.001) and 0.06 mg/l (p = 0.02),
respectively. The HDLc levels were lower in patients, on average
0.08 mmol/l (p,0.001). Expressed as percentages of the
calculated mean of the controls, we found that the total
cholesterol levels in patients were on average 3.8% higher,
triglyceride levels were 16.8% higher, apo B levels were 5.8%
higher and HDLc levels were 9.0% lower. We found no effect
modification between time and division into groups, indicating
that the variance of the lipid levels over time was similar in
both groups.
The magnitude of the observed difference in lipids between
patients and controls, as explained by CRP, was 4.0% for total
cholesterol, 0.4% for triglyceride, 3.6% for HDLc and 2.0% for
apo B levels. The influence of IgM-RF and anti-CCP on the
differences in total cholesterol, triglyceride, HDLc and apo B
levels was also minor, ranging from ,1% to a few per cent. In
addition, the other inflammation marker sPL-A2 had a similar
effect on the differences in lipids between the two groups and it
had no additional value above CRP (data not shown). Table 1
shows the differences in lipid levels between patients and
controls, after adjustment for the influence of CRP, IgM-RF and
anti-CCP.
To investigate the longitudinal relationship of inflammation
and serological markers with the various lipid levels, patients
and controls were combined into one group. It was shown that
CRP had a significant influence on total cholesterol, HDLc and
apo AI levels. An increase of 10 mg/l in CRP level was
associated with decreases of 0.1 mmol/l in total cholesterol
(p = 0.01), 0.04 mmol/l in HDLc (p,0.001) and 0.05 mg/l in
apo AI levels (p,0.001). We found no significant associations
for the other lipids. Looking at the serological markers, we only
found a small significant influence of IgM-RF on apo AI
(p = 0.02)—that is, an increase of 10 AU/ml in IgM-RF was
associated with a decrease of 0.005 g/l in apo AI. The final
analysis using this time course model yielded no evidence for a
time lag between the lipids and CRP, sPL-A2 or the serological
markers. Although the associations reported here were found in
the pooled population, it did not matter whether the person
was a patient who later developed rheumatoid arthritis or a
control, because the same significant relationship between
inflammation and serological markers with the lipid levels was
found in the separate groups.
DISCUSSION
Our study shows that the lipid profile of blood donors who later
developed rheumatoid arthritis is more atherogenic than that of
matched controls. This lipid profile is characterised by higher
total cholesterol, triglyceride and apo B levels and lower HDLc
levels. Even after adjusting for IgM-RF, anti-CCP and CRP
levels, the lipid profile remained more atherogenic in patients.
This phenomenon starts more than 10 years before the clinical
onset of rheumatoid arthritis.
The differences in the various lipid values are small but may
have clinical relevance, in the light of results from other
studies.28–30 For instance, in a placebo-controlled study with
fibrates, the differences in lipid values between groups
receiving active treatment and placebo were similar to those
found in our study and the patients treated with fibrates had
.20% risk reduction for cardiovascular disease.31
Contrary to the expectations, CRP had only a marginal
influence on the differences in lipid levels between patients and
controls. Another acute-phase reactant, sPL-A2, showed a
comparable, marginal influence on the differences in lipids
between patients and controls. The influence of CRP on lipid
levels was equal for both groups—that is, increase in of CRP
level was associated with a decrease in total cholesterol, HDLc,
apo AI and Lp(a) levels, and with an increase in triglycerides
and apo B, resulting in a higher atherogenic index (ie, ratio of
total cholesterol to HDLc).
Growing evidence indicates that inflammation has an
important role in the pathogenesis of cardiovascular disease,
particularly in atherosclerosis.10 In addition to a postulated
direct effect of inflammation on endothelial cells, there is
mounting evidence that inflammation can also increase the
cardiovascular risk by deterioration of the lipid profile. This is
supported by the demonstration of a decrease in HDLc and apo
AI levels and an increase in triglycerides and apo B levels
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during an acute-phase response.32 Other investigators found an
association between increase in lipids as oxidised low-density
lipoprotein cholesterol and proinflammatory cytokines as CRP,
interleukin 6 and tumour necrosis factor a.33 Our findings
confirm these effects of inflammation on the various lipid
concentrations. As the changes in CRP only explained a small
part of the observed differences in lipid levels that remained
after adjusting for CRP, an alternative explanation is required.
Two possible explanations are plausible. Firstly, in view of
the association between the development of rheumatoid
arthritis and a less favourable lipid profile, a (marginally)
deteriorated lipid profile may render a person more susceptible
to inflammation or inflammatory diseases. In other words, one
or more of the examined lipids could have a regulatory effect on
inflammation. Several reports show anti-inflammatory effects
of HDLc and particularly apo AI. It is suggested that apo AI is
able to inhibit interactions between T lymphocytes and
monocytes, thereby modulating the inflammatory response.34
Moreover, another study showed the ability of apo AI to inhibit
interleukin 1 and tumour necrosis factor a, which further
supports the theory of an active modulating role of lipids in
inflammation.35
Secondly, a less favourable lipid profile is related to the
development of rheumatoid arthritis by a common or linked
background. This could be a socioeconomic (including dietary)
or genetic background. A few studies have indicated a genetic
predisposition for dyslipidaemia in patients with rheumatoid
arthritis.36 Further unravelling of the human genome will
probably elucidate this predisposition. Further investigations
into genetic markers that could single out the population at risk
should be undertaken.
In summary, our study supports the observation that patients
with rheumatoid arthritis have a more atherogenic lipid profile
even in the preclinical phase of rheumatoid arthritis, which
ultimately could explain the increased cardiovascular risk in
patients with rheumatoid arthritis. Furthermore, we show that
inflammation is associated with a (further) deterioration of the
lipid profile. However, contrary to expectations, inflammation
can explain only a small part of the observed differences in
lipids between people who later develop rheumatoid arthritis
and controls. Whether lipids modulate the susceptibility to the
development of inflammatory diseases such as rheumatoid
arthritis remains to be elucidated.
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